Printed From:

SOLIQUA 100/33 is covered by 92% of national commercial insurance plans*

As of 11/6/2017

Now covered on 92% of commercial plans nationwide*

For your adult patients with T2DM uncontrolled on basal insulin (<60 Units daily) or lixisenatide as an adjunct to diet and exercise
Help more patients put high HbA1c% behind them

SOLIQUA 100/33

combines the powerful control of Lantus® and lixisenatide, a GLP-1 Receptor Agonist